Press Releases Kalohexis Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public OfferingJuly 7, 2026Kalohexis Appoints Xuan Hui, B.Med., M.S., Ph.D., as Director of Corporate StrategyJune 18, 2026Kalohexis Presents Data Highlighting Dual MC3R/MC4R Activation as a Novel Mechanism Designed to Drive Safer, Healthier and More Durable Weight Loss at ENDO 2026June 15, 2026Kalohexis Announces Publication in Nature Communications Highlighting Dual MC3R/MC4R Activation as a Novel, Durable Mechanism that Drives Weight LossMay 29, 2026Kalohexis Announces First Patients Dosed in First-in-Human Phase 1 Clinical Trial of 710GO for General ObesityMay 28, 2026Kalohexis Announces Poster Presentation at the American Association for Cancer Research Annual Meeting 2026April 17, 2026Kalohexis Appoints Tony Mitchell as Chief Financial OfficerMarch 31, 2026Kalohexis Announces Publication in Frontiers in Endocrinology Defining Design Criteria for Next-Generation Melanocortin Drugs for General ObesityMarch 25, 2026Kalohexis Emerges from Stealth to Advance First- and Best-in-Class Therapeutics Harnessing the Melanocortin System to Treat Obesity and Metabolic DiseasesMarch 19, 2026Endevica Bio Unveils Differentiated Mechanism for Durable Weight Loss in ObesityOctober 2, 2025 In the News Preventing Weight Loss Is Key to a Successful Cancer TreatmentFebruary 19, 2025GLP-1s and Vanishing Muscle MassDecember 4, 2024As Obese, Overweight Population Grows in the U.S., More Treatment Options Are NeededNovember 22, 2024Cachexia Research Targeting the Brain Holds Significant PromiseSeptember 25, 2024
Kalohexis Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public OfferingJuly 7, 2026
Kalohexis Presents Data Highlighting Dual MC3R/MC4R Activation as a Novel Mechanism Designed to Drive Safer, Healthier and More Durable Weight Loss at ENDO 2026June 15, 2026
Kalohexis Announces Publication in Nature Communications Highlighting Dual MC3R/MC4R Activation as a Novel, Durable Mechanism that Drives Weight LossMay 29, 2026
Kalohexis Announces First Patients Dosed in First-in-Human Phase 1 Clinical Trial of 710GO for General ObesityMay 28, 2026
Kalohexis Announces Poster Presentation at the American Association for Cancer Research Annual Meeting 2026April 17, 2026
Kalohexis Announces Publication in Frontiers in Endocrinology Defining Design Criteria for Next-Generation Melanocortin Drugs for General ObesityMarch 25, 2026
Kalohexis Emerges from Stealth to Advance First- and Best-in-Class Therapeutics Harnessing the Melanocortin System to Treat Obesity and Metabolic DiseasesMarch 19, 2026
As Obese, Overweight Population Grows in the U.S., More Treatment Options Are NeededNovember 22, 2024
